Tyrosinemia type 1, caused by mutations in the fumarylacetoacetate hydrolase gene (Fah), is characterized by severe liver injury. We earlier developed a tyrosinemic mouse model with two genetic defects, Fah and 4-hydroxyphenylpyruvate dioxygenase (Hpd) deficiencies. Apoptosis of hepatocytes was induced and an acute onset of liver failure occurred after administration of homogentisic acid (HGA), the intermediate metabolite between the enzymes HPD and FAH. Cytochrome c was released from mitochondria prior to liver failure in the Fah ؊/؊ Hpd؊/؊ double-mutant mice after the administration of HGA. In a cell-free system, the addition of fumarylacetoacetate induced the release of cytochrome c from the mitochondria. We also found that caspase inhibitors were highly effective in preventing the liver failure induced by HGA in the double-mutant mice. Therefore, fumarylacetoacetate apparently induces the release of cytochrome c, which in turn triggers activation of the caspase cascade in hepatocytes of subjects with hereditary tyrosinemia type 1.
Hereditary tyrosinemia type 1 (HT1) is caused by mutations in the fumarylacetoacetate hydrolase gene, Fah, which encodes the last enzyme in the tyrosine catabolic pathway (Fig. 1a) (1, 2) . HT1 patients show various phenotypes characterized by progressive liver failure during infancy and early development of hepatocellular carcinoma (2, 3) . In HT1 hepatocytes, various cellular events have been documented, including inhibition of enzyme activity, such as 4-hydroxyphenylpyruvate dioxygenase (HPD) and ␦-aminolevulinate dehydratase (4), aberrant gene expression (5) (6) (7) (8) , mutagenesis (9) , and carcinogenesis (2, 9, 10) . These events seem to be related to an aberrant metabolism as a result of a metabolic block at FAH; however, much has remained to be elucidated. FAA and͞or related chemicals are obvious candidates.
We recently developed a tyrosinemic mouse model with Fah and Hpd deficiencies (11) . Of the two FAH-deficient mice known, one is albino lethal c 14CoS , first described by Gluecksohn-Waelsch in 1979 (12) . These mice have a large deletion on chromosome 7, including the albino locus and the Fah gene (13, 14) . The homozygous mice are characterized by impairment of expression of hepatocyte-specific genes in the liver during perinatal periods (7, 8, 14) . The other FAH-deficient mice were generated by targeted disruption of the Fah gene (10, 15) . These mice show essentially the same phenotype and are neonatally lethal (10, 14, 15) ; however, the double-mutant Fah Ϫ/Ϫ Hpd Ϫ/Ϫ mice grow normally (11) . In humans, FAH deficiency causes liver disease (1, 2) ; however, Fah Ϫ/Ϫ Hpd Ϫ/Ϫ mice showed no evidence of liver disease and their phenotype was similar to that of Hpd Ϫ/Ϫ mice (III mice) (11, (16) (17) (18) . In earlier work, we expressed human HPD in the liver of Fah
mice, by using a recombinant adenovirus (11) , the result being a reopening of the tyrosine catabolic pathway in the liver at the step of oxidation of 4-hydroxyphenylpyruvate (Fig. 1a) . This manipulation led to rapid and massive apoptosis of hepatocytes and death followed. This model system paved the way toward investigation of processes involved in the cellular injury seen in cases of HT1.
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked ''advertisement'' in accordance with 18 U.S.C. §1734 solely to indicate this fact. Much attention has been directed to investigations on the role of the mitochondria in apoptosis (19) (20) (21) (22) (23) (24) (25) (26) . The Bcl-2 family of proteins, predominantly localized in outer mitochondrial membranes, can inhibit permeability transition (19, 20) and the release of apoptogenic proteins-e.g., cytochrome c-from mitochondria (21) (22) (23) (24) (25) . Cytochrome c is localized in the intermembrane space and on the surface of the inner mitochondrial membrane. Cytochrome c released from the mitochondria interacts with Apaf-1, caspase-9, and pro-caspase-3 to activate caspase-3 and the caspase cascade, leading to fragmentation of the nucleus (24) (25) (26) . Release of cytochrome c from the mitochondria may be an early event leading to apoptotic cell death.
We now report that the release of cytochrome c from mitochondria precedes liver failure in the Fah
mice. The addition of FAA induces the release of cytochrome c in a cell-free system. We propose that at least one of the signals for cell death in hepatocytes of HT1 is FAA. The liver failure noted in the Fah Ϫ/Ϫ Hpd Ϫ/Ϫ was prevented by previous administration of caspase inhibitors.
MATERIALS AND METHODS
Animals and Recombinant Viruses. The HPD-deficient mice (III mice) (16) (17) (18) and Fah Immunoblotting for FAH and HPD from liver samples was carried out with rabbit antiserum directed to recombinant human FAH and HPD (11, 18) .
Replication-defective recombinant adenoviruses, human adenovirus type 5 (Ad5) lacking the E1A, E1B, and E3 regions and bearing human FAH, HPD, or ornithine transcarbamoylase (OTC) were prepared, as described (18, 27, 28) . Expression of HPD is driven by the CAG promoter (28, 29) . The adenovirus was purified and titrated as described (30) .
In Vitro Experiments. Primary cultures of hepatocytes obtained from III and Fah Ϫ/Ϫ Hpd Ϫ/Ϫ mice were prepared as described by Ueno et al. (31) . Cells were counted and placed at a density of 2 ϫ 10 4 cells per well (2 cm 2 ) of the 24-well plate in William's medium E (WE) supplemented with 10% fetal calf serum, 2.5 M dexamethasone (Sigma), 1.0 M insulin (Sigma), and 5 ng͞ml epidermal growth factor (Wakunaga, Hiroshima, Japan). After plating, HGA was added (n ϭ 10) to the culture medium, or cells were transfected with AdHPD (n ϭ 8) for 1 h. Cells were incubated at 37°C for 24 h and harvested by trypsinization, and cell viability was assessed by the trypan blue exclusion method. For the DNA ladder apoptosis assay, chromosomal DNA was prepared from 1 ϫ 10 6 cells and analyzed as described (32) .
To determine whether retrieval of FAH function by transfection with AdFAH would contribute to HGA-or AdHPDinduced apoptosis, we transfected newly isolated hepatocytes with AdFAH (or AdOTC as a control) in a sterile plastic tube for 1 h at a multiplicity of infection (moi) of 5, then the cells were placed at a density of 2 ϫ 10 4 cells per well (2 cm 2 ) of the 24-well plate in the culture medium described above. After plating, HGA was added (n ϭ 4) to the culture medium, or transfection with AdHPD (n ϭ 4) was done for 1 h. After 24-h incubation, the viability was assessed. We next examined the effect of pretreated AdFAH at various moi values (0, 0.01, 0.1, 1, 10, and 100) in the presence or absence of treatment with 1 mM HGA or with AdHPD at moi 10.
To investigate the in vitro protective effects of apoptosis inhibitors, newly isolated hepatocytes were incubated for 1 h with Ac-Tyr-Val-Ala-Asp-CHO (YVAD) (n ϭ 4) or Ac-AspGlu-Val-Asp-CHO (DEVD) (n ϭ 4) (TaKaRa, Tokyo, Japan) at various concentrations (0, 0.1, 1, 10, 100, or 1000 M), then were treated with 1 mM HGA or with AdHPD at moi 10.
Evaluation of Cytochrome c Release from Mitochondria. Mice were killed, the livers were quickly removed, and mitochondria and S-100 cytosolic fraction (final volume, 7 ml) were prepared, as described by Schnaitman and Greenawalt (33) . A part of the S-100 fraction was filtered through a regenerated cellulose membrane with a mesh size of 5000 (Centrex, Iwaki Glass, Funabashi, Japan) to remove macromolecules. Immunoblots for cytochrome c were carried out with a mAb (7H8.2C12; PharMingen), and mouse IgG was detected with horseradish peroxidase (HRP)-conjugated anti-mouse IgG by using enhanced chemiluminescence (ECL). For analysis of cytochrome c release from mitochondria in a cell-free system, 1 mg of control mitochondria was incubated with 20 l of filtered S-100 fraction from the mice at 37°C for 2 h. After centrifugation at 7,000 ϫ g at 4°C for 10 min, the supernatant was carefully separated (the first 10 l was used and the remainder was discarded), then the mitochondrial pellet was suspended in 100 l of buffer A (0.25 M sucrose͞20 mM Hepes, pH 7.4). The supernatant (5 l) and mitochondrial solution (10 g of protein) were subjected to SDS͞15% PAGE and immunoblot analysis for cytochrome c. To investigate the effect of FAA and HGA on mitochondrial cytochrome c, 1 mg of control mitochondria in 20 l of buffer A was incubated with various concentrations of FAA and HGA at 37°C for 2 h. The supernatant (5 l) and mitochondrial suspension (10 g of protein) were carefully separated by centrifugation at 7,000 ϫ g at 4°C for 10 min, then subjected to SDS͞15% PAGE and immunoblot analysis for cytochrome c.
mice die from acute liver failure with massive apoptosis of hepatocytes within 24 h after intraperitoneal treatment with HGA (LD 50 ϭ 300 mg͞kg of body weight). At a dose of 800 mg͞kg of body weight, the mice died within several hours after the injection of HGA. To evaluate the effect of the caspase inhibitors YVAD or DEVD, mice were given YVAD intraperitoneally (10 mol in 500 l of PBS), and 2 h later these mice were given HGA intraperitoneally (800 mg͞kg in 100 l of PBS). The mice were killed 6 h after the HGA injection and tissues were examined histologically.
Biochemical Analysis. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were quantified by using a standard clinical automatic analyzer. Urine succinylacetone was quantified in a stable isotope dilution gas chromatography͞mass spectrometry assay (34) .
Histological Examinations. Livers were excised and immediately immersed into 10% neutralized formalin for 1 week prior to embedding, sectioning, and staining with hematoxylin and eosin. The TUNEL [terminal deoxynucleotidyltransferase (TdT)-mediated dUTP-digoxigenin nicked end labeling] procedure kit (ApopTag; Oncor, Gaithersburg, MD) was used to evaluate the ratio of apoptotic hepatocytes.
RESULTS

Apoptosis of Hepatocytes of Fah
mice carried an albino deletion (7, 8, (12) (13) (14) on chromosome 7 that disrupted the Fah gene, and a nucleotide substitution in the Hpd gene (16-18) on chromosome 5 that resulted in premature termination of translation and skipping of the constitutive exon ( Fig. 1 b-d) . As a result, both FAH and HPD proteins in the liver were absent ( Fig. 1 e and f ) . In these mice, the lethal phenotype of FAH deficiency completely disappeared with the introduction of HPD deficiency (Fig. 1a) , and their phenotypes were similar to those of Hpd Ϫ/Ϫ mice (III mice). Acute liver failure in the Fah Ϫ/Ϫ Hpd Ϫ/Ϫ mice was achieved either by exogenous in vivo expression of HPD protein in the liver (18) or by administration of HGA (11) . In liver sections, massive numbers of hepatocytes were nonviable with fragmentation of nuclei, and approximately 30-80% gave positive signals by in situ detection of DNA fragmentation (see Table 1 and Fig. 6d ). Thus, Fah
mice, which are phenotypically normal, can serve as a model of the visceral injuries of HT1 (11) .
We asked whether primary cultured hepatocytes from III and Fah
mice differed in their sensitivity to HGA (Fig. 2a ). There were significant differences in the sensitivity to HGA of cultured hepatocytes from Fah (Fig. 2b) . In this experiment, cultured hepatocytes were infected 24 h after plating with AdHPD at moi 0 to 100. In the control experiments, 90% of the III cells survived, even when the moi exceeded 10. However, the Fah
hepatocytes did not survive after infection with recombinant adenovirus when the moi was more than 10. The numbers of dead cells increased depending on the amounts of recombinant virus used in the experiments. These investigations indicated that reopening of the tyrosine catabolic pathway at the step of HPD in the cultured hepatocytes from Fah
mice resulted in rapid apoptosis because of an intrinsic process of cell death.
We then investigated whether exogenous expression of FAH in Fah
hepatocytes would prevent HGA-or AdHPD-induced apoptosis (Fig. 3) . The expression of human FAH in primary cultured cells was obtained by recombinant adenovirus expressing human FAH (AdFAH) (Fig. 3a) . The Fah
hepatocytes that express human FAH were resistant to the cell death induced by HGA (Fig. 3b) or AdHPD (Fig. 3c) , compared with results obtained by using recombinant adenovirus expressing human ornithine transcarbamoylase (AdOTC) (see legend for Fig. 3 ). These results confirmed that cell death seen in the liver of Fah mice showed no such effects (Fig. 4b) . These investigations indicate that there is a low molecular weight substance(s) in the cytosol of the liver of HGA-treated Fah
mice that induces the release of cytochrome c from mitochondria. HPLC analysis showed that FAA was present predominantly in the S-100 fraction. We next asked whether purified FAA would react with isolated mitochondria and cause a release of cytochrome c in a cell-free system. As shown in Fig. 4c , incubation of the purified FAA with control mitochondria resulted in a considerable release of cytochrome c into the medium. As FAA is a reagent that causes the release of cytochrome c from mitochondria, it is a candidate for the chemical that triggers apoptotic process in FAH-deficient hepatocytes.
Caspase Inhibitors Prevent Apoptotic Cell Death of Cultured Fah
؊/؊ Hpd ؊/؊ Hepatocytes. We also investigated the effects of caspase inhibitors on death of HGA-or AdHPDtreated hepatocytes. We used YVAD, which is a potent, selective, cell-permeating inhibitor of caspase-1, and DEVD, which specifically inhibits caspase-1 and caspase-3 (35, 36) . In the absence of YVAD and DEVD, 80-90% of Fah
hepatocytes underwent apoptosis 24 h after incubation with 1 mM HGA (Fig. 5a ) or after infection of AdHPD at moi 10 ( Fig.  5b) . However, addition of YVAD or DEVD to the medium markedly decreased the HGA-or AdHPD-induced apoptosis in Fah
hepatocytes. These effects were concentration dependent, and nearly 90% survived in the case of 1000 M YVAD in the medium, and nearly 100% with 100 M DEVD. Thus, these inhibitors block the cell death pathway triggered by the cytochrome c released from mitochondria into the cytosol by FAA. However, we did not examine durations of effects of these inhibitors exceeding 1 h. These data suggest that inhibition of this apoptotic process at the level of caspase can prevent the inevitable death of the Fah We expected that in vivo administration of caspase inhibitors YVAD or DEVD would protect the mice from acute liver failure. To evaluate the in vivo effect of these inhibitors on prevention of liver failure, Fah
mice were given 10 mol of YVAD (n ϭ 6) or DEVD (n ϭ 2) intraperitoneally 2 h before injection of 800 mg͞kg of body weight of HGA. All the treated animals were killed 6 h after the administration of HGA and examined for liver function (Table 1) (Table 1) . Nevertheless, urinary excretion of succinylacetone, which is derived from FAA and is a diagnostic marker of tyrosinemia type 1 (2, 3), markedly increased after injection of HGA. The levels of urinary succinylacetone in HGA-treated mice pretreated with YVAD were also high (not determined in DEVD-treated mice). Liver histology showed that previous administration of the inhibitor significantly reduced the numbers of apoptotic hepatocytes (Fig. 6 ). Although the long-term effects of a single administration of inhibitors remains to be determined, these in vivo observations do suggest that pretreatment with caspase inhibitors can prevent the liver injury induced by HGA in the Fah 
DISCUSSION
Our previous observations that liver injury in FAH deficiency is associated with apoptotic death of hepatocytes suggested that an intrinsic reagent(s) derived from HGA triggers the process of apoptosis and that the apoptotic hepatocyte death is the central feature of liver disease in HT1 (11) . In the present study, we reproduced apoptosis in primary cultured hepatocytes from Fah Ϫ/Ϫ Hpd Ϫ/Ϫ mice by retrieval of the tyrosine catabolic pathway at the step of HPD. The apoptosis of Fah Ϫ/Ϫ Hpd Ϫ/Ϫ cells was apparently due to an intrinsic process in hepatocytes. Cytochrome c is an essential macromolecule that initiates activation of the caspase cascade, leading to fragmentation of the nucleus (21) (22) (23) (24) (25) (26) . Release of cytochrome c from the mitochondria into the cytosol seems to be an essential step in initiating the process of apoptosis. This protein was released in the intrinsic process of apoptosis of Fah Ϫ/Ϫ Hpd Ϫ/Ϫ cells. In addition, the release of cytochrome c was caused by FAA, a primary metabolite associated with FAH deficiency and a candidate for causing visceral injury in HT1 (11) . Effective treatment of an HT1 patient with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) (2, 3, 37) , which inhibits HPD activity, and complete rescue of Fah Ϫ/Ϫ mice by null mutation of HPD (11) support this concept. We found here that FAA directly interacted with the mitochondria and induced the release of cytochrome c. On the basis of these observations, we propose that FAA is at least one agent responsible for apoptotic hepatocyte death in FAH deficiency.
If the attack against mitochondria by FAA and the subsequent activation of the caspase cascade are essential events in the cellular injury in FAH deficiency, inhibition of the caspase cascade should modify the liver phenotype of Fah Ϫ/Ϫ . Indeed, caspase inhibitors effectively prevented death of Fah
cells. In addition, the HGA-induced liver failure was prevented by the caspase inhibitor YVAD. Thus, activation of the caspase cascade plays an essential role in liver injury in FAH deficiency. In other words, the challenge directed to the mitochondria by FAA can be separated from the subsequent cell death process. While FAA with its alkylating potential (2, 7) seems to attack membranes of various cellular components, our observations suggest that a critical part of liver injury in FAH deficiency is activation of the cell death process. FAA seems to be a major metabolite responsible for the cell death signal via mitochondria. HT1 is a complex disease (2, 3) , in which many cellular events are affected, including inhibition of enzyme activity (4), aberrant gene expression (5) (6) (7) (8) , mutagenesis (9) , and carcinogenesis (2, 9, 10) , in addition to cell death. Among these events, inhibition of ␦-aminolevulinate dehydratase is caused by direct interaction of the enzyme protein with succinylacetone (38) , a derivative of FAA. Mutagenesis and carcinogenesis may be related to possible DNA damage, perhaps caused by FAA (7). Apoptosis followed by severe DNA damage has been observed in many cell types subjected to various insults (39, 40) . Cell death processes induced by the accumulation of FAA seem to be rapid. Because it is unlikely that DNA damage by FAA induces the apoptosis of hepatocytes in FAH deficiency, we speculate that FAA might directly attack the mitochondria, leading to apoptosis (short-term effect) and to DNA damage (long-term effect).
The clinical features of HT1 are not unique. There are several metabolic liver diseases that are difficult to distinguish from HT1 without specific tests. These similarities include the liver pathology. Diseases such as galactosemia type I and hereditary fructose intolerance are examples. In addition, other diseases related to neonatal liver failure syndrome show similar clinical and pathological findings (41) . These disorders are often characterized by progressive loss of hepatocytes without elevation of transaminases and impaired synthesis of blood proteins. In this context, modifications of cell death processes of metabolic liver diseases by caspase inhibitors, as shown in the present study, may have clinical significance.
